Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507274 | 0.79 | CA2 (0.42) | CA2CA1KMT2ACA5ACA9 | |
| SCHEMBL30170674 | 0.73 | KCNN4 (0.37) | KCNN4NFE2L2 | |
| SCHEMBL776996 | 0.72 | IDO1 (0.48) | CA2CA1LMNAKMT2A | |
| SCHEMBL17583209 | 0.72 | CA2 (0.39) | CA2KCNN4CA1LMNAKMT2A | |
| Ammonia Solution, Strong SCHEMBL28355658 | 0.71 | IDO1 (0.47) | CA2CA1LMNAKMT2A | |
| SCHEMBL29674450 | 0.71 | CA2 (0.39) | CA2CA1KMT2APTGS2 | |
| SCHEMBL508044 | 0.71 | CA2 (0.39) | CA2CA1KMT2APTGS2 | |
| SCHEMBL17583151 | 0.70 | KMT2A (0.46) | CA2CA1KMT2ACA9 | |
| SCHEMBL9276151 | 0.70 | CA1 (0.41) | CA2KCNN4SLC22A12CA1KCNE1 | |
| SCHEMBL28038586 | 0.70 | CA2 (0.40) | CA2KCNN4CA1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130253022-A1 | NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012074784-A2 | NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE | ADVANCED NEURAL DYNAMICS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253022-A1 | NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE | GRIN2A, GRIK2, GRIK5 | CA2 462/4885KCNN4 965/4885SLC22A12 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.